EUCTR2011-002913-12-FI进行中（未招募）1 期
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
AbbVie Deutschland GmbH & Co. KGKG0 个研究点目标入组 255 人开始时间: 2012年6月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 255
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
- •Must have a documented deleterious BRCA1 or BRCA2 germline mutation. The investigator should ensure that the testing is consistent with local guidelines, and clinical practice, and that the test uses either 1) direct DNA sequencing/multiplex ligation-dependent probe amplification (MLPA) or 2) a well-characterized methodology previously validated by sequencing, such as that used to assess founder mutations. If testing has been performed by a laboratory other than Sponsor core laboratory, subjects may be enrolled and must be re-tested by Sponsor core laboratory for confirmation of BRCA1 or BRCA2 germline mutations.
- •If HER2 positive (HER2 3+ by immunohistochemistry or amplification by fluorescence in situ hybridization [FISH > 2]), subjects must have received and progressed on at least one prior standard HER2-directed therapy or the subject must be ineligible to receive anti-HER2 therapy.
- •Measurable lesion by RECIST (version 1.1) on computed tomography (CT) scan (within 21 days of C1D1) in at least one site. If only a single measurable lesion exists, it cannot be a bone or cystic lesion. Bone-only, lymphangitic pulmonary metastases, and previously irradiated tumors will be considered nonmeasurable.
- •ECOG Performance status of 0 to 2.
- •Adequate hematologic, renal, and hepatic function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 45
排除标准
- •Received anticancer agent(s), an investigational agent, or radiotherapy within 28days or 5 half lives; whichever is shorter, prior to C1D1. Prior treatment with palliative local breast or bone lesion radiation (other than pelvis) can occur within 14 days of C1D1. Subjects experiencing a significant adverse effect or toxicity (Grade 3 or Grade 4), causally attributed to previous anticancer treatment that has not recovered to at least Grade 2 are excluded. Anticancer hormonal therapy must be stopped 7 days prior to C1D1. Subjects receiving bisphosphonates are eligible.
- •More than 1 prior line of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease. Regimens received in the adjuvant/neoadjuvant setting within the past 6 months will also be considered toward the maximum of 1 prior line of therapy. In order to count as a line of therapy, a cytotoxic agent must have been administered for at least 1 full cycle. Previous treatments with hormonal therapy (tamoxifen, aromatase inhibitors) and signal transduction agents (e.g., trastuzumab lapatinib, erlotinib, gefitinib, bevacizumab) are allowed and are not counted towards the prior line of therapy.
- •Prior therapy with temozolomide, a platinum agent, or a Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.
- •Prior taxane therapy for metastatic disease. Use of taxanes as adjuvant therapy is permitted, if given more than 6 months prior to C1D1.
- •A history of or evidence of brain metastases or leptomeningeal disease. Subjects with symptoms to suggest central nervous system (CNS) metastases should have a brain MRI within 21 days of enrollment to confirm the absence of CNS metastases. Contrast CT is acceptable for subjects who are unable to undergo a brain MRI.
- •A history of uncontrolled seizure disorder.
- •Pre-existing neuropathy from any cause in excess of Grade 1.
- •Known history of allergic reactions to cremophor-paclitaxel.
- •Clinically significant uncontrolled condition(s).
研究者
相似试验
进行中（未招募）
不适用
A Study of (a) Veliparib and Temozolomide or (b) Veliparib, Carboplatin and Paclitaxel or (c) Placebo, Carboplatin and Paclitaxel in patients with Breast CancerBRCA1 or BRCA2 mutation metastatic breast cancerMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002913-12-SKAbbott GmbH & Co. KG255
已完成
2 期
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancermetastatic breast cancerNL-OMON40393AbbVie B.V.7
进行中（未招募）
1 期
A Study of (a) Veliparib and Temozolomide or (b) Veliparib, Carboplatin and Paclitaxel or (c) Placebo, Carboplatin and Paclitaxel in patients with Breast CancerEUCTR2011-002913-12-HUAbbVie Deutschland GmbH & Co. KG255
进行中（未招募）
1 期
A Study of (a) Veliparib and Temozolomide or (b) Veliparib, Carboplatin and Paclitaxel or (c) Placebo, Carboplatin and Paclitaxel in patients with Breast CancerEUCTR2011-002913-12-CZAbbVie Deutschland GmbH & Co. KG255
进行中（未招募）
1 期
A Study of (a) Veliparib and Temozolomide or (b) Veliparib, Carboplatin and Paclitaxel or (c) Placebo, Carboplatin and Paclitaxel in patients with Breast CancerEUCTR2011-002913-12-BEAbbVie Deutschland GmbH & Co. KG294